Business
IDEAYA Biosciences, Inc. Reports Second Quarter 2021 Financial Results and Provides Business Update
- Strong balance sheet of ~$400 million cash, cash equivalents and marketable securities is anticipated to fund planned operations into 2025 - Enrolling
About this update from Ideaya Biosciences, Inc.
[{"type":"text","content":"- Strong balance sheet of ~$400 million cash, cash equivalents and marketable securities is anticipated to fund planned operations into 2025\n - Enrolling MTAP-deletion solid tumors patients into the IDE397 Phase 1 dose escalation and tumor biopsy cohorts; targeting to obtain additional clinical pharmacodynamic data, including plasma SAM and tumor SDMA, in the fourth quarter of 2021\n - Targeting development candidate nomination for each of potential first-in-class PARG and Pol Theta synthetic lethality (SL) programs in the fourth quarter of 2021, and advancing chemistry optimization of Werner Helicase and second MTAP-SL programs\n - Targeting clinical data update for darovasertib combination(s) in the fourth quarter of 2021; amended Pfizer clinical trial collaboration and supply agreement to enable expansion for 40 additional patients on darovasertib / crizotinib combination\n - Targeting FDA clearance in the first half of 2022 to initiate a Phase 1 clinical trial to evaluate darovasertib in GNAQ mutation-mediated rare diseases\n\n\nSOUTH SAN FRANCISCO, Calif., Aug. 10, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, provided a business update and announced financial results for the second quarter ended June 30, 2021.\n\n \n \n \n \n \n \n\n \n\"We reported clinical data across multiple programs in the second quarter of 2021, including early clinical pharmacodynamic data for IDE397 in MTAP-deletion patients, as well as overall survival data for darovasertib monotherapy and early clinical efficacy for the darovasertib / binimetinib and darovasertib / crizotinib combinations in metastatic uveal melanoma patients. We also continued to advance our broad synthetic lethality pipeline and platform, with two potential development candidates anticipated in the fourth quarter of 2021 and multiple potential first-in-class preclinical targets and programs advancing against genetically defined patient populations. These clinical data and our synthetic lethality pipeline demonstrate our clinical progress and commitment to deliver precision medicine oncology therapies to patients with high unmet medical needs,\" said Yujiro S. Hata, Chief Executive Officer and President of IDEAYA Biosciences. \nP...